https://dyvebio.com/ 2026-10-05T20:59:47+00:00 https://dyvebio.com/press-release/dyve-biosciences-announces-positive-results-from-pilot-study-in-gout-pain-at-european-crystal-network-workshop-2019/ 2019-03-20T00:00:00+00:00 https://dyvebio.com/press-release/dyve-biosciences-receives-fda-clearance-to-begin-phase-2-study-of-dyv-700-for-treatment-of-acute-gout-pain/ 2019-12-10T00:00:00+00:00 https://dyvebio.com/press-release/dyve-biosciences-announces-chuck-harbert-ph-d-to-join-as-chief-scientific-officer/ 2020-01-07T00:00:00+00:00 https://dyvebio.com/press-release/dyve-biosciences-hosting-key-opinion-leader-webinar-on-gout-and-dyv702/ 2021-11-15T00:00:00+00:00 https://dyvebio.com/press-release/dyve-biosciences-announces-research-and-development-collaboration-with-moffitt-cancer-center/ 2022-02-03T00:00:00+00:00 https://dyvebio.com/press-release/dyve-biosciences-to-present-at-the-32nd-annual-oppenheimer-healthcare-conference/ 2022-02-16T00:00:00+00:00 https://dyvebio.com/press-release/dyve-biosciences-to-present-at-the-biocom-california-global-life-science-partnering-conference/ 2022-02-22T00:00:00+00:00 https://dyvebio.com/press-release/dyve-biosciences-announces-the-appointment-of-nicholas-a-saccomano-ph-d-to-its-scientific-advisory-board/ 2022-03-01T00:00:00+00:00 https://dyvebio.com/press-release/dyve-biosciences-to-present-at-the-34th-annual-roth-conference/ 2022-03-09T00:00:00+00:00 https://dyvebio.com/press-release/dyve-biosciences-to-present-at-the-ubs-global-healthcare-conference/ 2022-05-04T00:00:00+00:00 https://dyvebio.com/press-release/dyve-biosciences-to-participate-in-the-bio-international-convention/ 2022-06-02T00:00:00+00:00 https://dyvebio.wpengine.com/wp-content/uploads/2023/03/Dyve-Biosciences-to-Present-at-the-2019-Annual-ACR-Meeting.pdf#new_tab 2023-03-06T08:32:32+00:00 https://dyvebio.wpengine.com/wp-content/uploads/2023/03/Dyve-Biosciences-to-Highlight-the-Power-and-Potential-of-Transdermal-Drug-Delivery-at-PODD-2019.pdf#new_tab 2023-03-06T08:34:31+00:00 https://dyvebio.wpengine.com/wp-content/uploads/2023/03/Dyve-Biosciences-to-Present-at-the-2019-BIO-Investor-Forum.pdf#new_tab 2023-03-06T08:35:00+00:00 https://dyvebio.wpengine.com/wp-content/uploads/2023/03/Dyve-AIS.pdf#new_tab 2023-03-06T08:35:28+00:00 https://dyvebio.com/press-release/dyve-to-present-at-partnership-in-drug-delivery-conference-podd/ 2023-03-31T13:44:20+00:00 https://dyvebio.com/press-release/dyves-targets-phase-2-study-abstract-presented-at-acr/ 2023-03-31T15:02:18+00:00 https://dyvebio.com/press-release/dyve-biosciences-appoints-tatyana-beldock-to-board-of-directors/ 2023-04-11T14:07:18+00:00 https://dyvebio.com/press-release/dyve-announces-poster-presentation-at-2023-aacr-annual-meeting/ 2023-04-17T15:03:17+00:00 https://dyvebio.com/press-release/dyve-biosciences-announces-phase-2-targets-study-of-dyv702-for-pain-associated-with-acute-gout-flares-showcased-in-podium-presentation-at-2022-eular-congress/ 2023-04-18T20:19:44+00:00 https://dyvebio.com/press-release/dyve-biosciences-presents-preclinical-data-from-lead-oncology-drug-candidate-dyv800-at-the-american-association-for-cancer-research-2023-annual-meeting/ 2023-04-24T12:58:34+00:00 https://dyvebio.com/press-release/dyve-biosciences-appoints-camilla-v-simpson-to-its-board/ 2024-07-11T08:12:10+00:00